HK1189218A1 - 氟烷基 -苯二氮呯酮化合物 - Google Patents

氟烷基 -苯二氮呯酮化合物

Info

Publication number
HK1189218A1
HK1189218A1 HK14101033.1A HK14101033A HK1189218A1 HK 1189218 A1 HK1189218 A1 HK 1189218A1 HK 14101033 A HK14101033 A HK 14101033A HK 1189218 A1 HK1189218 A1 HK 1189218A1
Authority
HK
Hong Kong
Prior art keywords
fluoroalkyl
bis
benzodiazepinone compounds
benzodiazepinone
compounds
Prior art date
Application number
HK14101033.1A
Other languages
English (en)
Inventor
Claude Quesnelle
Soong-Hoon Kim
Francis Lee
Ashvinikumar Gavai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1189218A1 publication Critical patent/HK1189218A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK14101033.1A 2011-03-22 2014-01-30 氟烷基 -苯二氮呯酮化合物 HK1189218A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466238P 2011-03-22 2011-03-22
PCT/US2012/030021 WO2012129353A1 (en) 2011-03-22 2012-03-22 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds

Publications (1)

Publication Number Publication Date
HK1189218A1 true HK1189218A1 (zh) 2014-05-30

Family

ID=45894701

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14101033.1A HK1189218A1 (zh) 2011-03-22 2014-01-30 氟烷基 -苯二氮呯酮化合物

Country Status (32)

Country Link
US (2) US8629136B2 (zh)
EP (1) EP2688873B1 (zh)
JP (1) JP5873923B2 (zh)
KR (1) KR101948347B1 (zh)
CN (1) CN103717576B (zh)
AR (1) AR085471A1 (zh)
AU (1) AU2012230904B2 (zh)
BR (1) BR112013024059B1 (zh)
CA (1) CA2830902C (zh)
CL (1) CL2013002690A1 (zh)
CO (1) CO6771446A2 (zh)
CY (1) CY1116423T1 (zh)
DK (1) DK2688873T3 (zh)
EA (1) EA022530B1 (zh)
ES (1) ES2534080T3 (zh)
HK (1) HK1189218A1 (zh)
HR (1) HRP20150273T1 (zh)
IL (1) IL228534A (zh)
MA (1) MA35036B1 (zh)
MX (1) MX2013010420A (zh)
MY (1) MY161233A (zh)
PE (1) PE20140626A1 (zh)
PL (1) PL2688873T3 (zh)
PT (1) PT2688873E (zh)
RS (1) RS53843B1 (zh)
SG (1) SG193555A1 (zh)
SI (1) SI2688873T1 (zh)
SM (1) SMT201500091B (zh)
TN (1) TN2013000372A1 (zh)
TW (1) TWI530489B (zh)
UY (1) UY33961A (zh)
WO (1) WO2012129353A1 (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072526B1 (en) 2009-10-16 2018-09-26 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CN104822665A (zh) * 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
EP2897954B1 (en) * 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047391A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
WO2014047370A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
JP2016515625A (ja) * 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
CN104356082B (zh) * 2014-10-31 2016-07-13 厦门大学 一类取代杂环衍生物及其制备方法
CN104352488B (zh) * 2014-10-31 2016-08-31 厦门大学 一类取代杂环衍生物在制备治疗疼痛药物中的应用
US10174015B2 (en) 2014-10-31 2019-01-08 Xiamen University Substituted heterocyclic derivative, preparation method and use thereof
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN104892532B (zh) * 2015-05-20 2017-09-08 成都理工大学 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺
ES2928343T3 (es) 2015-07-22 2022-11-17 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de RSV
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
WO2017123884A1 (en) 2016-01-15 2017-07-20 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
KR102511024B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
IL268737B2 (en) 2017-02-16 2024-02-01 Enanta Pharm Inc Processes for the preparation of benzodiapine derivatives
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
EP3438128B1 (en) * 2017-08-04 2020-05-20 Alzheimur 2012 S.L. Anti-presenilin antibody for use in the prevention and/or treatment of cancer
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
CN111343990B (zh) * 2017-11-13 2023-08-04 英安塔制药有限公司 苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2019215585A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
US20210244745A1 (en) 2018-05-06 2021-08-12 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
WO2019222298A1 (en) * 2018-05-15 2019-11-21 Bristol-Myers Squibb Company Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
WO2019222231A1 (en) * 2018-05-15 2019-11-21 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
KR20210013184A (ko) * 2018-05-24 2021-02-03 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물과 면역요법제를 포함하는 조성물 및 이의 사용 방법
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US20220241294A1 (en) * 2019-05-15 2022-08-04 Ayala Pharmaceuticals Inc. Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
AU2020357452A1 (en) 2019-10-04 2022-05-12 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
AU2021337602A1 (en) 2020-09-03 2023-04-20 Bristol-Myers Squibb Company Polymorphs of bis(fluoroalkyl)-1,4-benzodiazepinone compounds and uses thereof
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
EP4255409A1 (en) 2020-12-07 2023-10-11 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
BR112023016970A2 (pt) 2021-02-26 2023-10-10 Enanta Pharm Inc Compostos heterocíclicos antivirais
EP4346816A2 (en) 2021-06-02 2024-04-10 Cellestia Biotech AG Compounds for use in a method for treating an autoimmune and inflammatory disease
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
JP2000507587A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2000028331A1 (en) 1998-11-12 2000-05-18 Du Pont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
BR9917082A (pt) 1998-12-24 2001-11-06 Du Pont Pharm Co Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
DE60042425D1 (de) 1999-04-30 2009-07-30 Univ Michigan Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997700A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
EP1268454A1 (en) 2000-03-31 2003-01-02 Bristol-Myers Squibb Pharma Company Succinoylamino heterocycles as inhibitors of a-beta protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
MXPA02009755A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
KR101125899B1 (ko) 2002-09-20 2012-04-12 애로우 쎄라퓨틱스 리미티드 벤조디아제핀 유도체 및 이를 함유하는 약학 조성물
NZ541324A (en) 2003-02-04 2008-10-31 Hoffmann La Roche Malonamide derivatives as gamma-secretase inhibitors
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
JP4571639B2 (ja) 2003-09-09 2010-10-27 エフ．ホフマン−ラ ロシュ アーゲー ガンマ−セクレターゼの活性を阻害するマロンアミド誘導体
EP1795198A1 (en) 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
RU2440342C2 (ru) 2006-03-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг МАЛОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ γ-СЕКРЕТАЗЫ
JP5001372B2 (ja) 2006-09-20 2012-08-15 エフ．ホフマン−ラ ロシュ アーゲー ４−オキソ−２，３，４，５−テトラヒドロ−ベンゾ［ｂ］［１，４］ジアゼピン誘導体
CA2694209C (en) 2007-08-14 2013-09-17 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
BRPI0906831A2 (pt) 2008-01-11 2019-09-24 Hoffmann La Roche uso de um inibidor de gama-secretase para tratamento de câncer
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor

Also Published As

Publication number Publication date
PE20140626A1 (es) 2014-05-30
BR112013024059A2 (pt) 2016-12-06
BR112013024059B1 (pt) 2022-01-25
AR085471A1 (es) 2013-10-02
KR101948347B1 (ko) 2019-02-14
SG193555A1 (en) 2013-11-29
HRP20150273T1 (hr) 2015-06-19
CA2830902C (en) 2019-10-29
CL2013002690A1 (es) 2014-02-14
EA022530B1 (ru) 2016-01-29
KR20140027956A (ko) 2014-03-07
SI2688873T1 (sl) 2015-04-30
JP2014511840A (ja) 2014-05-19
IL228534A0 (en) 2013-12-31
CN103717576A (zh) 2014-04-09
TWI530489B (zh) 2016-04-21
CN103717576B (zh) 2015-11-25
CO6771446A2 (es) 2013-10-15
AU2012230904B2 (en) 2016-03-31
AU2012230904A1 (en) 2013-11-07
TN2013000372A1 (en) 2015-01-20
EP2688873B1 (en) 2015-01-21
MY161233A (en) 2017-04-14
JP5873923B2 (ja) 2016-03-01
EA201391324A1 (ru) 2014-03-31
NZ616876A (en) 2014-08-29
PL2688873T3 (pl) 2015-06-30
SMT201500091B (it) 2015-05-05
MA35036B1 (fr) 2014-04-03
US8629136B2 (en) 2014-01-14
US20120245151A1 (en) 2012-09-27
US20140100365A1 (en) 2014-04-10
DK2688873T3 (en) 2015-04-27
US8822454B2 (en) 2014-09-02
TW201309656A (zh) 2013-03-01
EP2688873A1 (en) 2014-01-29
MX2013010420A (es) 2013-10-01
CA2830902A1 (en) 2012-09-27
CY1116423T1 (el) 2017-02-08
WO2012129353A1 (en) 2012-09-27
UY33961A (es) 2012-09-28
PT2688873E (pt) 2015-04-14
RS53843B1 (en) 2015-08-31
ES2534080T3 (es) 2015-04-17
IL228534A (en) 2017-02-28

Similar Documents

Publication Publication Date Title
HK1189218A1 (zh) 氟烷基 -苯二氮呯酮化合物
HRP20170352T8 (hr) Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
IL229007A0 (en) Dihydroisoxazole compounds kill parasites
PT2710018T (pt) Compostos macrocíclicos como inibidores de proteína quinases
GB201109763D0 (en) Compounds
GB201118652D0 (en) New compounds
GB201106395D0 (en) Compounds
GB201118654D0 (en) New compounds
SI2776436T1 (sl) Nove spojine
GB201107197D0 (en) Compounds
SG11201402145RA (en) Novel organophosphorus compounds based on anthracenetriol
GB201106814D0 (en) New compounds
EP2771012A4 (en) NEW CONNECTIONS
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201118613D0 (en) Compounds
HK1191946A1 (zh) 新型六氫吡咯並咪唑酮化合物
GB201119590D0 (en) New compounds I
GB201119703D0 (en) Compounds
GB201115828D0 (en) Compounds
GB201115827D0 (en) Compounds
GB201115829D0 (en) Compounds
GB201114195D0 (en) Compounds
GB201111440D0 (en) Compounds